Elena has over 10 years of experience in venture biotech with deep knowledge in evaluating investment opportunities. Since joining Pharmstandard Ventures (formerly Inbio Ventures) in 2014, she was involved in looking for new projects, financial modeling, deal structuring as well as analysis of portfolio companies' performance. She currently serves as a Board member at Avelas Biosciences, and a Board Observer at TearSolutions and enGene.

Prior to Pharmstandard Ventures Elena worked as an Investment Manager at Bioprocess Capital Ventures, one of the first Russian venture funds specializing in life sciences. Earlier in her career, Elena held several positions in consulting companies, including Roland Berger Strategy Consultants.

Elena graduated from Plekhanov Russian University of Economics with honors. She received her MSc in economics and mathematics with focus on risk management.

Vadim joined Pharmstandard Ventures in 2019. He combines both scientific and financial skills. Vadim has extensive experience in corporate banking and investments at major Russian private and state banks. He obtained a degree in biophysics from the Faculty of Physics at Moscow State University. His skills in the finance of innovation were boosted by New Economic School's course "Venture Capital and Private Equity" specially designed to develop a real-world understanding of venture capital from the perspective of the investor.

Anton Vyatchanin was previously a scientific expert at IBC Generium since 2011. His main activity was focused on scientific assessment of incoming projects and management several of those that have been approved to be developed within the company. Before that he participated in development of several biologics in CJSC Biocad as a project leader within biochemical part of the projects.

He got a Ph.D. in biochemistry from Institute of Gene Biology RAS in 2008 after he graduated from Biology faculty of Moscow State University in 2005. His Ph.D. work was devoted to phage-display selection of mini-antibodies from libraries of single-chain antibodies of two-humped camels. His experience relates to protein biochemistry, molecular biology, biological drug development.

Before joining Pharmstandard Ventures (formerly Inbio Ventures), Svetlana served as a head of preclinical research department at IBC Generium, a Russian biotechnology company, since 2012. During this time, under her supervision more than 20 preclinical research programs of potential drugs were developed and carried out, whereas some of them have already successfully entered the stage of clinical evaluation. Previously she worked in the field of somatic stem cell nuclear transfer for obtaining the embryonic stem cells without using of human oocytes, and she has developed a technology of efficient reprogramming of human somatic stem cells to a pluripotent state.

Svetlana has more than 8 years of experience in stem cell biology and tissue engineering (creation of human bone, cartilage and skin), in 2007 she received Ph.D. in Immunology and Biotechnology. Her Ph.D. work was devoted to the evaluation of human stem cells from adipose tissue, the creation of three-dimensional structures of human cartilage tissues with the assessment of potential clinical application for regenerative medicine. She underwent specialization at Biology faculty of Moscow State University in the field of Molecular Biology in 2001. She has experience in the Department of Surgery and Intensive Care in Emergency hospital after she graduated from Medical college in 1995.

Before joining Pharmstandard Ventures (formerly Inbio Ventures) Alexey Evseev did postdoc in University of Texas Medical Center in San Antonio focusing on neuron and muscle physiology, ion channels and cell signaling pathways.

Alexey has extensive experience in cell biology, signaling pathways and general physiology.

He received his Ph.D. from Russian Academy of Sciences in 2010. His Ph.D. work is about mechanism of endocytosis and mechanics of plasma membrane fission. Results of his study are published in Cell journal.

Gleb has more than 2 years of working experience in biomedical venture business. Before joining Pharmstandard ventures in 2021 he worked as an analyst at Unicorn Capital Partners - $65M venture fund in Russia with investment focus on breakthrough therapeutics, medical devices and digital health solutions. He was responsible for start-up scouting, scientific assessment, market analysis and preparation for the investment committee.

Gleb obtained his MSc degree in bioorganic chemistry at Lomonosov Moscow State University. He has several scientific papers published in Q1 journals devoted to aptamers and their bioanalytical applications.